Baricitinib (INCB28050, LY3009104)

  Cat. No.:  DC5064   Featured
Baricitinib (INCB28050, LY3009104)
Chemical Structure
1187594-09-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2).
Cas No.: 1187594-09-7
Chemical Name: 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
Synonyms: INCB028050; INCB-028050; INCB 028050; LY3009104; LY-3009104; LY 3009104; Baricitinib; Olumiant
SMILES: N(S(CC)(=O)=O)1CC(N2C=C(C3N=CN=C4NC=CC4=3)C=N2)(CC#N)C1
Formula: C16H17N7O2S
M.Wt: 371.41688
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:
Description: Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. Significant efficacy, as assessed by improvements in clinical, histologic and radiographic signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3. Diminution of inflammatory Th1 and Th17 associated cytokine mRNA levels was observed in the draining lymph nodes of treated rats. INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematologic effects. These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient For significant activity in autoimmune disease models.For the detailed information of Baricitinib (INCB28050, LY3009104), the solubility of Baricitinib (INCB28050, LY3009104) in water, the solubility of Baricitinib (INCB28050, LY3009104) in DMSO, the solubility of Baricitinib (INCB28050, LY3009104) in PBS buffer, the animal experiment (test) of Baricitinib (INCB28050, LY3009104), the cell expriment (test) of Baricitinib (INCB28050, LY3009104), the in vivo, in vitro and clinical trial test of Baricitinib (INCB28050, LY3009104), the EC50, IC50,and Affinity of Baricitinib (INCB28050, LY3009104), Please contact DC Chemicals.
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC5064 Baricitinib (INCB28050, LY3009104) Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2).